OSE Immunotherapeutics (XPAR:OSE) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics COGS-to-Revenue?

OSE Immunotherapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was €0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was €0.87 Mil.

OSE Immunotherapeutics's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. OSE Immunotherapeutics's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

OSE Immunotherapeutics COGS-to-Revenue Historical Data

The historical data trend for OSE Immunotherapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics COGS-to-Revenue Chart

OSE Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

OSE Immunotherapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

OSE Immunotherapeutics COGS-to-Revenue Calculation

OSE Immunotherapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	2.227
	=	0.00

OSE Immunotherapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.869
	=	0.00

OSE Immunotherapeutics (XPAR:OSE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

OSE Immunotherapeutics's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.869
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

OSE Immunotherapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

6OP:Germany

Address

22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website

http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines